



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/130075/2012

European Medicines Agency decision P/0045/2012

of 29 February 2012

on the acceptance of a modification of an agreed paediatric investigation plan for sunitinib (Sutent) (EMA-000342-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0045/2012

of 29 February 2012

on the acceptance of a modification of an agreed paediatric investigation plan for sunitinib (Sutent) (EMA-000342-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/35/2009 issued on 24 February 2009,

Having regard to the application submitted by Pfizer Limited on 21 October 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 January 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for sunitinib (Sutent), hard capsule, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Pfizer Limited, Ramsgate Road, CT13 9NJ Sandwich, United Kingdom.

Done at London, 29 February 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/942297/2011

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000342-PIP01-08-M02

Scope of the application

Active substance(s):

Sunitinib

Invented name:

Sutent

Condition(s):

Treatment of gastro-intestinal stromal tumour

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Hard capsule

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pfizer Limited

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Pfizer Limited submitted to the European Medicines Agency on 21 October 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/35/2009 issued on 24 February 2009.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 16 November 2011.

Scope of the modification

The timelines of a study in the paediatric investigation plan was modified and a measure was added.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 13 January 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of gastro-intestinal stromal tumour

The waiver applies to:

- Children from birth to less than 6 years;
- for hard capsule for oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of gastro-intestinal stromal tumour

2.1.1. Indication(s) targeted by the PIP

Treatment of gastro-intestinal stromal tumour

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years

2.1.3. Pharmaceutical form(s)

Hard capsule, oral use

2.1.4. Studies

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical		Not applicable.
Clinical	2	Study 1: Open-label, single-agent, single-arm, multi-centre, dose escalation trial of sunitinib to evaluate safety and pharmacokinetics in children aged 2 to less than 18 years with refractory solid tumours Study 2: Open-label, single-agent, single-arm, multi-centre trial of sunitinib to evaluate safety and pharmacokinetics in children aged 6 years to less than 18 years with gastro-intestinal stromal tumours Study 3: Measure to extrapolate efficacy to the paediatric population

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2014
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of gastro-intestinal tumour

Authorised indication(s):

Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance.

2. Treatment of renal cell carcinoma

Authorised indication(s):

Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.

3. Treatment of pancreatic neuroendocrine tumours

Authorised indications:

Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.

EU Number	Invented name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/06/347/001	Sutent	12.5 mg	Capsule, hard	Oral use	bottle (HDPE)	30 capsules
EU/1/06/347/002	Sutent	25 mg	Capsule, hard	Oral use	bottle (HDPE)	30 capsules
EU/1/06/347/003	Sutent	50 mg	Capsule, hard	Oral use	bottle (HDPE)	30 capsules
EU/1/06/347/004	Sutent	12.5 mg	Capsule, hard	Oral use	blister (Aclar/PVC)	28 capsules
EU/1/06/347/005	Sutent	25 mg	Capsule, hard	Oral use	blister (Aclar/PVC)	28 capsules
EU/1/06/347/006	Sutent	50 mg	Capsule, hard	Oral use	blister (Aclar/PVC)	28 capsules
EU/1/06/347/007	Sutent	37.5 mg	Capsule, hard	Oral use	bottle (HDPE)	30 capsules
EU/1/06/347/008	Sutent	37.5 mg	Capsule, hard	Oral use	blister (Aclar/PVC)	28 capsules